Please assess the completion status of the following clinical trial:

Trial Title: A Study of S5G4T-1 in the Treatment of Papulopustular Rosacea

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Participants must sign an Institutional Review Board (IRB) approved written informed consent for this study.~2. Male and female 18 years of age and older.~3. Participants must have clinical diagnosis of moderate to severe rosacea.~4. Have a minimum total of 15 and a maximum of 70 total inflammatory lesions (papules and/or pustules) including those present on the nose.~5. Have 2 nodules or less.~Exclusion Criteria:~1. Females, who are pregnant, breastfeeding, or planning a pregnancy within the period of their study participation or were found to have positive pregnancy test at Baseline or screening visits.~2. Presence of more than 2 facial nodules or any nodule greater than 1 centimeter (cm).~3. Current or past ocular rosacea (for example, conjunctivitis, blepharitis, or keratitis) of sufficient severity to require topical or systemic antibiotics.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- S5G4T-1 (Type: EXPERIMENTAL): Participants will topically apply S5G4T-1 cream, once daily to face for 12 weeks.
- S5G4T-2 Vehicle Cream (Type: PLACEBO_COMPARATOR): Participants will topically apply S5G4T-2 vehicle cream, once daily to face for 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).